Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12276 - 12300 of 14522 in total
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
TTX-MC138 is an antisense oligonucleotide targeting miR-10b. It is under investigation for the treatment of various metastatic cancers.
Investigational
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells.
Investigational
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)
Investigational
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
Investigational
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Investigational
SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, amino acids, peptides, nucleosides, and nucleotides. It is under investigation for the treatment of cutaneous sulfur mustard-induced injury.
Investigational
Matched Description: … derived from calf's blood comprising electrolytes, trace minerals, amino acids, peptides, nucleosides, and
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and
Investigational
Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3).
Investigational
Bi104 is being investigated for the treatment of Angelman syndrome.
Investigational
RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.
Investigational
Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
Investigational
Matched Description: … Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety …
Avizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).
Investigational
Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).
Investigational
Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)).
Investigational
Matched Description: … Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and
Displaying drugs 12276 - 12300 of 14522 in total